BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (May 2015)

23 slides from BioSpecifics Technologies's investor presentation, May 18, 2015

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development & commercialization of INJECTABLE COLLAGENASE <i BioSpecifics May 2015

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding

  3. Slide 3: BioSpecifics is a profitable, commercial-stage biopharma company

    BioSpecifics is a profitable, commercial-stage biopharma company receiving increasing revenues for sales of collagenase clostridium histolyticum or CCH (XIAFLEX®) by partner Endo. Future revenue growth opportunities emerging from commitment to clinical development of new potential indications for CC

  4. Slide 4: Unlocking Vast Potential of CCH

    Unlocking Vast Potential of CCH First-in-class, minimally invasive nonsurgical treatment for conditions caused by collagen accumulation with limited current treatment options BioSpecifics has positive clinical results in 12 indications: Dupuytren’s contracture’ Frozen shoulder Scarred tendons Peyron

  5. Slide 5: XIAFLEX 1Q15 Commercial Highlights

    XIAFLEX 1Q15 Commercial Highlights ~12,200 demand vials were shipped January 1, 2015 through March 31, 2015 ~6,300 vials in Peyronie’s disease ~5,900 vials in Dupuytren's contracture Represents year-over-year growth of approximately 114% (1014 vs. 1Q15) Continued traction with certified physicians a

  6. Slide 6: XIAFLEX U.S. Commercial Sales

    XIAFLEX U.S. Commercial Sales Approved in adult Dupuytren's contracture patients with a palpable cord in March 2010 Approved for treatment of Peyronie's disease in December 2013 1Q15 sales in Peyronie’s disease (~6,300 vials) already exceeded sales of Dupuytren’s contracture (~5,900 vials) Approxima

  7. Slide 7: XIAFLEX for Dupuytren's Contracture

    XIAFLEX for Dupuytren’s Contracture First and Only FDA- and EMA-Approved Nonsurgical Treatment Collagen cord in hand causing one or more fingers to contract toward the Definition palm; limits range of motion and impairs quality of life 300K patients diagnosed annually in the U.S. Treatment of up to

  8. Slide 8: XIAFLEX for Peyronie's Disease

    XIAFLEX for Peyronie’s Disease First and Only FDA- and EMA-Approved Nonsurgical Treatment Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Definition & Associated with pain with erection, penile shortening, erectile Key Complications dysfunctio

  9. Slide 9: XIAFLEX Pipeline Programs

    XIAFLEX Pipeline Programs Future Revenue-Generating Opportunities Frozen Shoulder Next trial to initiate by year-end 2015 Syndrome Cellulite Phase 2b to initiate by year-end 2015 *Human Lipoma Complete enrollment in Phase 2 in 2Q15 Canine Endo has license for further development Lipoma *Uterine Posi

  10. Slide 10: CCH for Frozen Shoulder Syndrome

    CCH for Frozen Shoulder Syndrome Potential to be Only FDA Approved Nonsurgical Therapy Definition & Complications Inflammation and thickening of shoulder capsule due to collagen Limits range of motion of shoulder Common available treatment options are often painful and can Potential to be require an

  11. Slide 11: Phase 2b Study of CCH in Frozen Shoulder

    Phase 2b Study of CCH in Frozen Shoulder Study Design Double-blind, placebo-controlled study evaluating safety and efficacy in Stage 2 (frozen stage) unilateral idiopathic frozen shoulder Objective & Rationale : Phase 2b study based on positive, statistically significant results in Phase 2a study of

  12. Slide 12: Phase 2b Study Results of CCH in FSS

    Phase 2b Study Results of CCH in FSS Next Trial Expected to Start by Year-End 2015 Strong, similar drug effect for key measures including forward flexion, shoulder abduction, external and internal rotation across both Phase 2a and Phase 2b trials Similar CCH patient improvement in pain seen across b

  13. Slide 13: CCH for Cellulite

    CCH for Cellulite Phase 2b Trial to Initiate by Year-End 2015 Definition Significant Market Opportunity as First Nonsurgical Therapy Positive Top-line Results Reported from Phase 2a Study in 3Q14 Source: Endo International, ple Skin dimpling as a result of collagen fibrous septae, occurring mainly o

  14. Slide 14: CCH for Cellulite

    CCH for Cellulite Positive Top-line Data from Phase 2a Study Top-line Data from Phase 2a Study Mid and high level CCH doses demonstrated statistically significant improvement in cellulite across all endpoints 68% of mid and high dose groups reported being “Satisfied” or “Very Satisfied” with treatme

  15. Slide 15: CCH for Human Lipomas

    CCH for Human Lipomas Phase 2 Opt-In Study Managed by BioSpecifics Encapsulated deposits of benign fatty tumors; detected as bulges Pinon under the skin Potential to be No FDA-approved pharmaceutical therapies available Only Approved Nonsurgical Therapy Surgery not practical for patients with multip

  16. Slide 16: Positive Phase Clinical Trial Results

    Positive Phase 2 Clinical Trial Results Reported in January 2014 Open label, dose escalation Phase 2 trial: Statistically significant (p<0.0001) reduction in primary endpoint of visible surface area of lipoma as measured by caliper, combining all patients Patients in highest dose group (75% of comme

  17. Slide 17: CCH for Lipomas in Canines

    CCH for Lipomas in Canines Key Complications Potential to be Only Approved Nonsurgical Therapy Chien-804 Trial Results Lipomas can seriously restrict motion in older dogs Surgery can be risky due to the use of general anesthesia - especially for older dogs 1.7M dogs affected in the U.S. annually Bas

  18. Slide 18: CCH for Uterine Fibroids

    CCH for Uterine Fibroids Endo Encouraged by Results Reported to Date Ee Definition & Pain, decreased fertility, BR = in Key Complicati miscarriage, heavy menstrual (Aso) diets bleeding and frequent urination i =) | 8 Potential to be Primary indication for 000 025 050 1.00 200 : » Collagenase Dose [m

  19. Slide 19: Endo Partnership for Development and Commercialization of CCH

    Endo Partnership for Development and Commercialization of CCH >$57.7M Received to Date Future Payments Due to BioSpecifics from Endo Endo Opt-In Rights Milestone Payments from Endo Partnerships $57.7M received in licensing, sublicensing, milestone, COGS, and royalty payments as of March 31, 2015 Low

  20. Slide 20: Corporate Highlights

    Corporate Highlights Projected Revenue Growth from Higher Royalties Vast opportunity for growth in revenues from XIAFLEX sales and approval of CCH in new indications Strong IP portfolio Long-term patent protection for injectable collagenase: Dupuytren’s Contracture: XIAFLEX has Drug product composit

  21. Slide 21: Consistently Profitable Annually

    Consistently Profitable Annually Quarterly Financial Highlights (unaudited) For the quarter ended 03/31/15 03/31/14 Cash and equivalents, and investments $24,994,544 $16,907,795 Income Statement Revenues $5,606,454 $2,757,601 Other income 18,353 11,799 Costs and expenses (2,042,587) (1,629,009) Prov

  22. Slide 22: Anticipated Upcoming Milestones

    Anticipated Upcoming Milestones Upcoming Milestones *Human A Lipomas QO Complete enrollment in Phase 2 placebo-controlled opt-in trial in 2Q15 See oe ae O Refining development plan Peyronie’s — . Disease O Building sales momentum in the EU Dupuytren’s Q Decision on approval by PMDA in Japan expected

  23. Slide 23: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development & commercialization of INJECTABLE COLLAGENASE ee ; BioSpecifics May 2015

BioSpecifics Technologies — Investor Presentation (May 2015) on 6ix